Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions: towards MRD for all

Roland P. Kuiper; Patricia G. Hoogeveen; Reno Bladergroen; Freerk van Dijk; Edwin Sonneveld; Frank N. van Leeuwen; Judith Boer; Irina Sergeeva; Harma Feitsma; Monique L. den Boer; Vincent H.J. van der Velden

doi:10.1111/bjh.17744

Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions: towards MRD for all

Roland P. Kuiper, Patricia G. Hoogeveen, Reno Bladergroen, Freerk van Dijk, Edwin Sonneveld, Frank N. van Leeuwen, Judith Boer, Irina Sergeeva, Harma Feitsma, Monique L. den Boer, Vincent H.J. van der Velden^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

8 Citations (Scopus)

60 Downloads (Pure)

Abstract

Minimal residual disease (MRD) diagnostics are implemented in most clinical protocols for patients with acute lymphoblastic leukaemia (ALL) and are mostly performed using rearranged immunoglobulin (IG) and/or T-cell receptor (TR) gene rearrangements as molecular polymerase chain reaction targets. Unfortunately, in 5–10% of patients no or no sensitive IG/TR targets are available, and patients therefore cannot be stratified appropriately. In the present study, we used fusion genes and genomic deletions as alternative MRD targets in these patients, which retrospectively revealed appropriate MDR stratification in 79% of patients with no (sensitive) IG/TR target, and a different risk group stratification in more than half of the cases.

Original language	English
Pages (from-to)	888-892
Number of pages	5
Journal	British Journal of Haematology
Volume	194
Issue number	5
DOIs	https://doi.org/10.1111/bjh.17744
Publication status	Published - 1 Sept 2021

Bibliographical note

Funding Information:
We gratefully acknowledge the support and contribution of Željko Antić, Simon V. van Reijmersdal, Lionel Morgado, Alex Hoogkamer, Marjolein Bakker, and Hester de Groot. We thank Erik Splinter, Petra Klous, and Max van Min for supporting the TLA analyses. This project was supported by KIKA (grant 308).

Funding Information:
We gratefully acknowledge the support and contribution of ?eljko Anti?, Simon V. van Reijmersdal, Lionel Morgado, Alex Hoogkamer, Marjolein Bakker, and Hester de Groot. We thank Erik Splinter, Petra Klous, and Max van Min for supporting the TLA analyses. This project was supported by KIKA (grant 308).

Publisher Copyright:
© 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd

Research programs

EMC MM-02-54-03

Access to Document

10.1111/bjh.17744Licence: CC BY-NC-ND

Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletionsFinal published version, 624 KBLicence: CC BY-NC-ND

Cite this

Kuiper, R. P., Hoogeveen, P. G., Bladergroen, R., van Dijk, F., Sonneveld, E., van Leeuwen, F. N., Boer, J., Sergeeva, I., Feitsma, H., den Boer, M. L., & van der Velden, V. H. J. (2021). Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions: towards MRD for all. British Journal of Haematology, 194(5), 888-892. https://doi.org/10.1111/bjh.17744

@article{046d984bcc3e4ecd8e535c44262337af,

title = "Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions: towards MRD for all",

abstract = "Minimal residual disease (MRD) diagnostics are implemented in most clinical protocols for patients with acute lymphoblastic leukaemia (ALL) and are mostly performed using rearranged immunoglobulin (IG) and/or T-cell receptor (TR) gene rearrangements as molecular polymerase chain reaction targets. Unfortunately, in 5–10\% of patients no or no sensitive IG/TR targets are available, and patients therefore cannot be stratified appropriately. In the present study, we used fusion genes and genomic deletions as alternative MRD targets in these patients, which retrospectively revealed appropriate MDR stratification in 79\% of patients with no (sensitive) IG/TR target, and a different risk group stratification in more than half of the cases.",

author = "Kuiper, \{Roland P.\} and Hoogeveen, \{Patricia G.\} and Reno Bladergroen and \{van Dijk\}, Freerk and Edwin Sonneveld and \{van Leeuwen\}, \{Frank N.\} and Judith Boer and Irina Sergeeva and Harma Feitsma and \{den Boer\}, \{Monique L.\} and \{van der Velden\}, \{Vincent H.J.\}",

note = "Funding Information: We gratefully acknowledge the support and contribution of {\v Z}eljko Anti{\'c}, Simon V. van Reijmersdal, Lionel Morgado, Alex Hoogkamer, Marjolein Bakker, and Hester de Groot. We thank Erik Splinter, Petra Klous, and Max van Min for supporting the TLA analyses. This project was supported by KIKA (grant 308). Funding Information: We gratefully acknowledge the support and contribution of ?eljko Anti?, Simon V. van Reijmersdal, Lionel Morgado, Alex Hoogkamer, Marjolein Bakker, and Hester de Groot. We thank Erik Splinter, Petra Klous, and Max van Min for supporting the TLA analyses. This project was supported by KIKA (grant 308). Publisher Copyright: {\textcopyright} 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley \& Sons Ltd",

year = "2021",

month = sep,

day = "1",

doi = "10.1111/bjh.17744",

language = "English",

volume = "194",

pages = "888--892",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "John Wiley \& Sons Inc.",

number = "5",

}

Kuiper, RP, Hoogeveen, PG, Bladergroen, R, van Dijk, F, Sonneveld, E, van Leeuwen, FN, Boer, J, Sergeeva, I, Feitsma, H, den Boer, ML & van der Velden, VHJ 2021, 'Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions: towards MRD for all', British Journal of Haematology, vol. 194, no. 5, pp. 888-892. https://doi.org/10.1111/bjh.17744

TY - JOUR

T1 - Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions

T2 - towards MRD for all

AU - Kuiper, Roland P.

AU - Hoogeveen, Patricia G.

AU - Bladergroen, Reno

AU - van Dijk, Freerk

AU - Sonneveld, Edwin

AU - van Leeuwen, Frank N.

AU - Boer, Judith

AU - Sergeeva, Irina

AU - Feitsma, Harma

AU - den Boer, Monique L.

AU - van der Velden, Vincent H.J.

N1 - Funding Information: We gratefully acknowledge the support and contribution of Željko Antić, Simon V. van Reijmersdal, Lionel Morgado, Alex Hoogkamer, Marjolein Bakker, and Hester de Groot. We thank Erik Splinter, Petra Klous, and Max van Min for supporting the TLA analyses. This project was supported by KIKA (grant 308). Funding Information: We gratefully acknowledge the support and contribution of ?eljko Anti?, Simon V. van Reijmersdal, Lionel Morgado, Alex Hoogkamer, Marjolein Bakker, and Hester de Groot. We thank Erik Splinter, Petra Klous, and Max van Min for supporting the TLA analyses. This project was supported by KIKA (grant 308). Publisher Copyright: © 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd

PY - 2021/9/1

Y1 - 2021/9/1

N2 - Minimal residual disease (MRD) diagnostics are implemented in most clinical protocols for patients with acute lymphoblastic leukaemia (ALL) and are mostly performed using rearranged immunoglobulin (IG) and/or T-cell receptor (TR) gene rearrangements as molecular polymerase chain reaction targets. Unfortunately, in 5–10% of patients no or no sensitive IG/TR targets are available, and patients therefore cannot be stratified appropriately. In the present study, we used fusion genes and genomic deletions as alternative MRD targets in these patients, which retrospectively revealed appropriate MDR stratification in 79% of patients with no (sensitive) IG/TR target, and a different risk group stratification in more than half of the cases.

AB - Minimal residual disease (MRD) diagnostics are implemented in most clinical protocols for patients with acute lymphoblastic leukaemia (ALL) and are mostly performed using rearranged immunoglobulin (IG) and/or T-cell receptor (TR) gene rearrangements as molecular polymerase chain reaction targets. Unfortunately, in 5–10% of patients no or no sensitive IG/TR targets are available, and patients therefore cannot be stratified appropriately. In the present study, we used fusion genes and genomic deletions as alternative MRD targets in these patients, which retrospectively revealed appropriate MDR stratification in 79% of patients with no (sensitive) IG/TR target, and a different risk group stratification in more than half of the cases.

UR - https://www.scopus.com/pages/publications/85111631657

U2 - 10.1111/bjh.17744

DO - 10.1111/bjh.17744

M3 - Article

C2 - 34337744

AN - SCOPUS:85111631657

SN - 0007-1048

VL - 194

SP - 888

EP - 892

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 5

ER -

Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions: towards MRD for all

Abstract

Bibliographical note

Research programs

Access to Document

Other files and links

Fingerprint

Cite this